Skip to main content

Radiation Oncology

Ausgabe 1/2008

Inhalt (44 Artikel)

Open Access Research

Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer

Jasper Yuen, George Rodrigues, Kristina Trenka, Terry Coad, Slav Yartsev, David D'Souza, Michael Lock, Glenn Bauman

Open Access Research

Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?

Carsten Nieder, Adam Pawinski, Nicolaus H Andratschke, Michael Molls

Open Access Research

Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?

Matthias Guckenberger, Kurt Baier, Anne Richter, Dirk Vordermark, Michael Flentje

Open Access Research

Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons

Zahra Taheri-Kadkhoda, Thomas Björk-Eriksson, Simeon Nill, Jan J Wilkens, Uwe Oelfke, Karl-Axel Johansson, Peter E Huber, Marc W Münter

Open Access Short report

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

Bernhard Berger, Claus Belka

Open Access Research

Dosimetric consequences of the shift towards computed tomography guided target definition and planning for breast conserving radiotherapy

Hans Paul van der Laan, Wil V Dolsma, John H Maduro, Erik W Korevaar, Johannes A Langendijk

Open Access Study protocol

High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina

Sushil Beriwal, Dwight E Heron, Robert Mogus, Robert P Edwards, Joseph L Kelley, Paniti Sukumvanich

Open Access Research

High-dose-rate brachytherapy for soft tissue sarcoma in children: a single institution experience

Gustavo A Viani, Paulo E Novaes, Alexandre A Jacinto, Celia B Antonelli, Antonio Cassio A Pellizzon, Elisa Y Saito, João V Salvajoli

Open Access Study protocol

Study protocol of the German "Registry for the Detection of Late Sequelae after Radiotherapy in Childhood and Adolescence" (RiSK)

Tobias Bolling, Andreas Schuck, Hildegard Pape, Christian Rube, Barbara Pollinger, Beate Timmermann, Rolf D Kortmann, Karin Dieckmann, Normann Willich

Open Access Research

The effect of radio-adaptive doses on HT29 and GM637 cells

Silke B Schwarz, Pamela M Schaffer, Ulrike Kulka, Birgit Ertl-Wagner, Roswitha Hell, Moshe Schaffer

Open Access Methodology

Testing the portal imager GLAaS algorithm for machine quality assurance

G Nicolini, E Vanetti, A Clivio, A Fogliata, G Boka, L Cozzi

Open Access Short report

High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients

Irene M Lips, Homan Dehnad, Carla H van Gils, Arto E Boeken Kruger, Uulke A van der Heide, Marco van Vulpen

Open Access Research

Reproducibility and geometric accuracy of the fixster system during hypofractionated stereotactic radiotherapy

Peter Lindvall, Per Bergström, Per-Olov Löfroth, Roger Henriksson, A Tommy Bergenheim

Open Access Research

A psychoeducational intervention reduces the need for anesthesia during radiotherapy for young childhood cancer patients

Sonja Haeberli, Michael A Grotzer, Felix K Niggli, Markus A Landolt, Claudia Linsenmeier, Roland A Ammann, Nicole Bodmer

Open Access Short report

Effect of prolonging radiation delivery time on retention of gammaH2AX

Vitali Moiseenko, Judit P Banáth, Cheryl Duzenli, Peggy L Olive

Open Access Research

In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol

Robert Michael Hermann, Hendrik Andreas Wolff, Hubertus Jarry, Paul Thelen, Carsten Gruendker, Margret Rave-Fraenk, Heinz Schmidberger, Hans Christiansen

Open Access Research

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study

David Goldblum, Pirus Ghadjar, Juergen Curschmann, Richard Greiner, Daniel Aebersold

Open Access Commentary

Surgery vs. radiotherapy in localized prostate cancer. Which is best?

Stefan Welz, Maximilian Nyazi, Claus Belka, Ute Ganswindt

Open Access Methodology

The GLAaS algorithm for portal dosimetry and quality assurance of RapidArc, an intensity modulated rotational therapy

Giorgia Nicolini, Eugenio Vanetti, Alessandro Clivio, Antonella Fogliata, Stine Korreman, Jiri Bocanek, Luca Cozzi

Open Access Review

The impact of functional imaging on radiation medicine

Nidhi Sharma, Donald Neumann, Roger Macklis

Open Access Review

Neuropsychological testing and biomarkers in the management of brain metastases

Andrew Baschnagel, Pamela L Wolters, Kevin Camphausen

Open Access Study protocol

Randomized multicenter trial on the effect of radiotherapy for plantar Fasciitis (painful heel spur) using very low doses – a study protocol

Marcus Niewald, M Heinrich Seegenschmiedt, Oliver Micke, Stefan Gräber

Open Access Research

Reirradiation of recurrent breast cancer with and without concurrent chemotherapy

Florian Würschmidt, Jörg Dahle, Cordula Petersen, Claudia Wenzel, Matthias Kretschmer, Christoph Bastian

Open Access Study protocol

FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma

Letizia Deantonio, Debora Beldì, Giuseppina Gambaro, Gianfranco Loi, Marco Brambilla, Eugenio Inglese, Marco Krengli

Open Access Research

A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma

Tom Budiharto, Karin Haustermans, Eric Van Cutsem, Werner Van Steenbergen, Baki Topal, Raymond Aerts, Nadine Ectors, Didier Bielen, Dirk Vanbeckevoort, Laurence Goethals, Chris Verslype

Open Access Research

The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Prakash Chinnaiyan, Meihua Wang, Amyn M Rojiani, Philip J Tofilon, Arnab Chakravarti, K Kian Ang, Hua-Zhong Zhang, Elizabeth Hammond, Walter Curran Jr, Minesh P Mehta

Open Access Commentary

SCLC extensive disease – treatment guidance by extent or/and biology of response?

Franziska Eckert, Arndt-Christian Müller

Open Access Research

Motion compensation with a scanned ion beam: a technical feasibility study

Sven Oliver Grözinger, Christoph Bert, Thomas Haberer, Gerhard Kraft, Eike Rietzel

Open Access Research

Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking

Pirus Ghadjar, Jacqueline Vock, Daniel Vetterli, Peter Manser, Roland Bigler, Jan Tille, Axel Madlung, Frank Behrensmeier, Roberto Mini, Daniel M Aebersold

Open Access Review

Normal tissue toxicity after small field hypofractionated stereotactic body radiation

Michael T Milano, Louis S Constine, Paul Okunieff

Open Access Research

Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT

Judit Boda-Heggemann, Frederick Marc Köhler, Hansjörg Wertz, Michael Ehmann, Brigitte Hermann, Nadja Riesenacker, Beate Küpper, Frank Lohr, Frederik Wenz

Open Access Research

Pre-segmented 2-Step IMRT with subsequent direct machine parameter optimisation – a planning study

Klaus Bratengeier, Jürgen Meyer, Michael Flentje

Open Access Research

Dose volume histogram analysis of normal structures associated with accelerated partial breast irradiation delivered by high dose rate brachytherapy and comparison with whole breast external beam radiotherapy fields

Alexandra J Stewart, Desmond A O'Farrell, Robert A Cormack, Jorgen L Hansen, Atif J Khan, Subhakar Mutyala, Phillip M Devlin

Open Access Research

Radiation-induced skin injury in the animal model of scleroderma: implications for post-radiotherapy fibrosis

Sanath Kumar, Andrew Kolozsvary, Robert Kohl, Mei Lu, Stephen Brown, Jae Ho Kim

Open Access Research

Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life

CM van Rij, WD Oughlane-Heemsbergen, AH Ackerstaff, EA Lamers, AJM Balm, CRN Rasch

Open Access Research

Investigation of the usability of conebeam CT data sets for dose calculation

Anne Richter, Qiaoqiao Hu, Doreen Steglich, Kurt Baier, Jürgen Wilbert, Matthias Guckenberger, Michael Flentje

Open Access Research

Outcome in recurrent head neck cancer treated with salvage-IMRT

Gabriela Studer, Klaus W Graetz, Christoph Glanzmann

Open Access Research

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Damien C Weber, Thomas Zilli, Franz Buchegger, Nathalie Casanova, Guy Haller, Michel Rouzaud, Philippe Nouet, Giovanna Dipasquale, Osman Ratib, Habib Zaidi, Hansjorg Vees, Raymond Miralbell

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.